Using autophagy to improve immune function in HIV patients who use methamphetamine
Targeting autophagy to reduce inflammasome-mediated inflammation and immune dysfunction in HIV and methamphetamine use
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA LOS ANGELES · NIH-11097146
This study is looking at how using methamphetamine impacts the immune system of people living with HIV who are on treatment, and it’s exploring whether a special treatment can help boost their immune response and lower inflammation to improve their health.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA LOS ANGELES (nih funded) |
| Locations | 1 site (LOS ANGELES, UNITED STATES) |
| Trial ID | NIH-11097146 on ClinicalTrials.gov |
What this research studies
This research investigates how methamphetamine use affects the immune system in individuals living with HIV, particularly those on antiretroviral therapy. It aims to understand the molecular mechanisms by which methamphetamine impairs immune function and increases inflammation. The study explores the potential of autophagy inducers, like rapamycin, to enhance immune responses and reduce inflammation in these patients. By examining the effects of these treatments in humanized mouse models, the research seeks to identify new therapeutic strategies for improving health outcomes in this vulnerable population.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who also use methamphetamine and are receiving antiretroviral therapy.
Not a fit: Patients who do not have HIV or do not use methamphetamine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance immune function and reduce inflammation in HIV patients who also struggle with methamphetamine addiction.
How similar studies have performed: Previous studies have shown promising results with autophagy inducers in improving immune function and reducing inflammation, suggesting a potential for success in this novel application.
Where this research is happening
LOS ANGELES, UNITED STATES
- UNIVERSITY OF CALIFORNIA LOS ANGELES — LOS ANGELES, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHEN, ANJIE — UNIVERSITY OF CALIFORNIA LOS ANGELES
- Study coordinator: ZHEN, ANJIE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome, Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome, Acquired Immunodeficiency Syndrome Virus